Literature DB >> 832656

Distribution of pentobarbital and diphenylhydantoin between plasma and cells in blood: effect of salicylic acid, temperature and total drug concentration.

M Ehrnebo, I Odar-Cederlöf.   

Abstract

The binding of pentobarbital, diphenylhydantoin and salicylic acid to cells in blood was found to be independent of total drug concentration within therapeutic levels. Salicylic acid displaced pentobarbital and diphenylhydantoin from plasma protein binding sites, but high levels of salicylic acid had no effect on the distribution of the other two drugs to washed blood cells. Thus, in whole blood the presence of salicylic acid decreased the fraction of pentobarbital or diphenylhydantoin bound to plasma proteins and increased the fraction of the drug in plasma water and in blood cells. Diphenylhydantoin was shown not to be bound irreversibly to blood cells and equilibration in between the inside and outside of the cells was found to be rapid (within 5 min), even at high concentrations. Binding to washed blood cells was the same at 37 degress C and 25 degrees C, in contrast to plasma protein binding. It is pointed out that these effects may cause certain analytical errors, resulting in changes in plasma concentration if plasma is separated at a low temperature.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832656     DOI: 10.1007/BF00561786

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution.

Authors:  P K Lunde; A Rane; S J Yaffe; L Lund; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1970 Nov-Dec       Impact factor: 6.875

2.  A rapid method for the determination of salicylate binding by the use of ultrafilters.

Authors:  R Spector; D T Korkin; A V Lorenzo
Journal:  J Pharm Pharmacol       Date:  1972-10       Impact factor: 3.765

3.  Pentazocine binding to blood cells and plasma proteins.

Authors:  M Ehrnebo; S Agurell; L O Boréus; E Gordon; U Lönroth
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

4.  Pharmacokinetics and distribution properties of pentobarbital in humans following oral and intravenous administration.

Authors:  M Ehrnebo
Journal:  J Pharm Sci       Date:  1974-07       Impact factor: 3.534

5.  Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding.

Authors:  I Odar-Cederlöf; O Borgå
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

Review 6.  The binding of drugs by plasma proteins.

Authors:  M C Meyer; D E Guttman
Journal:  J Pharm Sci       Date:  1968-06       Impact factor: 3.534

7.  Permeability of human erythrocytes to ammonia and weak acids.

Authors:  R A Klocke; K K Andersson; H H Rotman; R E Forster
Journal:  Am J Physiol       Date:  1972-04

8.  Enhancement of pentobarbital narcosis by drugs competing on the serum protein binding.

Authors:  G Pagnini; R Di Carlo; F Di Carlo; E Genazzani
Journal:  Biochem Pharmacol       Date:  1971-12       Impact factor: 5.858

9.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

10.  Complex formation between macromolecules and drugs. IX. The competition between two sulfa drugs and phenobarbital, pentobarbital or phenoxymethyl penicillin for binding sites on human serum albumin.

Authors:  S O Nilsson; A Agren; J O Brånstad; U Meresaar
Journal:  Acta Pharm Suec       Date:  1973-12
View more
  2 in total

Review 1.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of phenytoin.

Authors:  A Richens
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.